Rate My Professor Shaun Fleming

Associate Professor Shaun Fleming serves as a clinical and laboratory haematologist at the Australian Centre for Blood Diseases within Monash University's Faculty of Medicine. He obtained his MBBS with Honours from Monash University in 2005, followed by fellowships of the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australasia (FRCPA) in 2014, and a PhD. His postgraduate training in haematology took place at St Vincent's Hospital Melbourne, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, and Melbourne Pathology, culminating in an Acute Leukaemia Fellowship at the Alfred Hospital. In his clinical roles, Fleming is Head of the Myeloid Diseases Service at Alfred Health, where he directs the acute leukaemia and myeloid disorders program. He holds co-appointments as a haematologist and bone marrow transplant physician at both Monash Health and Alfred Health, facilitating allogeneic stem cell transplantation for patients, including assessment, risk stratification, and ongoing management. Additionally, he is a chimeric antigen receptor T-cell (CART) physician and maintains an external position as a haematologist at Epworth Healthcare. His clinical expertise encompasses malignant haematological disorders such as acute leukaemia, lymphoma, myelodysplasia, and other blood disorders, as well as consultative haematology for issues like blood count abnormalities, paraproteins, and thrombosis management.

Fleming's academic interests centre on acute leukaemia, with a focus on novel therapies for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), measurable residual disease (MRD) assessment, and the integration of machine learning and artificial intelligence for prognostic scoring in haematology. He leads a research team conducting clinical trials in myelodysplasia and myeloid disorders, serving as principal investigator on phase I first-in-human, phase II, and phase III studies. As co-chair of the Acute Lymphoblastic Leukaemia working party for the Australasian Leukaemia and Lymphoma Group (ALLG), he has spearheaded national initiatives, including the ALLG ALL08 study delivering novel therapies to older adults with ALL. Notable publications include the 'Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)' (2025), 'CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy' (2025), 'ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL' (2025), 'Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments' (2025), and 'Neurotoxicity associated with chimeric antigen receptor T-cell therapy' (2025). His contributions advance therapeutic strategies and clinical practices in haematological malignancies.